Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07282639 · ClinicalTrials.gov registry record · NA
App-Based Certified Diabetes Education Therapy (AB-CDE)
A NA study, sponsored by Oregon Health and Science University.
- Not yet
- Registry status
- NA
- Development phase
- 99
- Enrollment target
NCT07282639: Clinical Trial NA study, sponsored by Oregon Health and Science University.
NCT07282639 is a NA study that has not yet begun recruiting, run by Oregon Health and Science University. The registered enrollment target is 99 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07282639, a NA study, has not yet begun recruiting, sponsored by Oregon Health and Science University.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 99 participants
- Enrollment target
Study Summary
The purpose of this study is to learn more about a smartphone application (app) called DailyDose, an investigational decision support tool that may help in managing your diabetes. DailyDose tracks your continuous glucose monitoring (CGM) data, insulin use, and exercise, and uses this information to provide personalized recommendations for insulin dosing and carbohydrate intake during exercise or low blood sugar events. We want to find out if DailyDose can help lower blood sugar levels as measured by the hemoglobin A1c (HbA1c) test.
Primary Outcome
Hemoglobin A1c will be processed by a central lab. Lower values generally indicate better glucose control.
Interventions
- DEVICE DailyDose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2026-01-15 |
| Est. Completion | 2027-12-15 |
| Phase | NA |
What is known before NCT07282639 opens enrollment
NCT07282639 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 99 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 1 intervention - of which DailyDose is the first listed.
NCT07282639 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07282639 about?
NCT07282639 is a clinical study titled "App-Based Certified Diabetes Education Therapy (AB-CDE)". The purpose of this study is to learn more about a smartphone application (app) called DailyDose, an investigational decision support tool that may help in managing your diabetes. DailyDose tracks your continuous glucose monitoring (CGM) data, insulin use, and exercise, and uses this information to ...
What is the current status of trial NCT07282639?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 99 participants. The study started on 2026-01-15. Estimated completion is 2027-12-15.
What interventions are being tested in trial NCT07282639?
The interventions under investigation include: DailyDose (DEVICE).
Who is sponsoring clinical trial NCT07282639?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07282639's enrollment target sits among peer trials
99 920th of 2000 higher than 1,079 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03965234 · 99 participants · Phase 1
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
- NCT04022616 · 99 participants
Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients
- NCT04042844 · 99 participants · Phase 2
A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)
- NCT04143724 · 99 participants · Phase 2
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI